PRE Stock Forecast & Price Target

Prenetics Global is viewed positively because IM8 is scaling rapidly in a large, fast-growing dietary supplements market, with ARR of nearly $200 million as of May 31st, 2026 and continuing revenue momentum that lifted FY26 guidance to $210 million-$220 million and points to more than $400 million in FY27. Its fundamentals are strengthened by science-backed, clinically validated products, NSF and cGMP quality standards, and a subscription-heavy model that is improving customer economics, including LTV/CAC of 3:1, higher AOV of $240 in 1Q26, and faster cash collection. The recently closed $1 billion growth financing from General Catalyst’s CVF, plus approximately $139.7 million of cash and investments as of 5/31, reduces balance-sheet risk and supports continued marketing-led growth without equity dilution.

Prenetics Global is facing a fragile path to profitability because sustainable growth depends on converting users into paying subscribers and retaining them, while IM8’s largest expense remains sales and marketing. The shift toward longer-duration quarterly subscribers has increased per-customer acquisition costs, and that burden could rise further if digital ad rates, platform algorithms, or privacy rules weaken marketing efficiency, especially as DTC fulfillment adds freight, warehousing, packaging, and last-mile costs. Its outlook is also pressured by a highly competitive, lightly regulated dietary supplement market, plus geopolitical and supply-chain risk tied to Hong Kong operations, mainland China uncertainty, and tariffs or trade restrictions.